Welcome to our dedicated page for Krystal Biotech news (Ticker: KRYS), a resource for investors and traders seeking the latest updates and insights on Krystal Biotech stock.
Krystal Biotech reports news on its commercial genetic-medicines business, led by VYJUVEK, a redosable gene therapy approved in the United States, Europe, and Japan for dystrophic epidermolysis bullosa. Company updates commonly cover VYJUVEK revenue and global commercialization, manufacturing and platform developments, and regulatory actions tied to its HSV-1-based gene delivery technology.
Recurring clinical and scientific updates address investigational programs including KB407 for cystic fibrosis, KB707 for advanced or metastatic non-small cell lung cancer, KB111 for Hailey-Hailey disease, KB803 for corneal abrasions in DEB patients, and additional HSV-1-based vectors. News also includes quarterly operating results, conference presentations, FDA designations, and investor-event participation.
Krystal Biotech (KRYS) will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York.
Management is scheduled for a fireside chat at 3:55 p.m. ET and will also host investor meetings during the day. A webcast of the presentation will be available starting at 3:55 p.m. ET and posted in the Investors section of the company’s website.
Krystal Biotech (NASDAQ: KRYS) reported 2Q 2026 VYJUVEK net product revenue of $119.2 million, up 24% year over year, with a 95% gross margin and total VYJUVEK revenue of $965.9 million since launch. Net income for the quarter was $54.8 million, and the company ended June 30, 2026 with $1.1 billion in cash, cash equivalents and investments.
Krystal highlighted expanding global VYJUVEK adoption, including ongoing European pricing discussions and UK approval, and expects launches in Spain and Italy by year-end. Multiple registrational or late-stage programs are progressing across ophthalmology (KB803, KB801), respiratory (KB407, KB408), dermatology (KB111), oncology (KB707 inhaled and intratumoral) and aesthetics (KB304), with several interim data readouts anticipated in 2H 2026 and 2027. Full-year 2026 non-GAAP combined R&D and SG&A expense is guided to $175–$195 million.
Krystal Biotech (NASDAQ: KRYS) will report its second quarter 2026 financial results on Monday, August 3, 2026, before the U.S. market opens. Management will host a conference call and webcast at 8:30 a.m. ET that day. A live webcast will be available online, with a replay accessible for at least 30 days via the Investors section of the company’s website.
S&P Dow Jones Indices announced changes to the S&P MidCap 400 and S&P SmallCap 600 effective before trading on July 24 and July 27, 2026. On July 24, Krystal Biotech (KRYS) will move from the S&P SmallCap 600 to join the S&P MidCap 400, replacing Taylor Morrison Home (TMHC). Tutor Perini (TPC) will be added to the S&P SmallCap 600, replacing Krystal Biotech.
According to S&P Dow Jones Indices, Berkshire Hathaway (BRK.A/BRK.B) is acquiring Taylor Morrison Home, with closing expected on or about July 24, pending final conditions. On July 27, V2X (VVX) will join the S&P SmallCap 600, replacing Avanos Medical (AVNS), which is being acquired by American Industrial Partners, also pending final closing conditions.
Krystal Biotech (NASDAQ:KRYS) received United Kingdom MHRA marketing authorization for VYJUVEK to treat wounds in patients with dystrophic epidermolysis bullosa (DEB) with COL7A1 mutations, from birth. VYJUVEK is the first genetic medicine approved in the UK for DEB.
The approval includes flexible administration at home or in healthcare settings, including by patients or caregivers. VYJUVEK met UK Orphan Designation criteria, enabling up to 12 years of market exclusivity. Launch timing will depend on completion of reimbursement procedures.
Krystal Biotech (NASDAQ: KRYS) will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026 in Las Vegas. Krish S. Krishnan, chairman and CEO, will join a fireside chat at 11:20 am PT and hold investor meetings the same day. A webcast will be available beginning at 11:20 am PT on the company’s Investors website.
Krystal Biotech (NASDAQ: KRYS) reported $116.4 million in 1Q 2026 VYJUVEK global net product revenue and $1.0 billion in cash and investments at quarter end.
Clinical updates: KB803 enrollment complete (16 patients) with top-line IOLITE results expected 4Q 2026; KB801 enrollment ongoing with full enrollment of 60 patients and data expected by year-end. FDA granted platform technology designation to vectors for KB407 and KB111. FY2026 non-GAAP R&D+SG&A guidance: $175–$195 million.
Krystal Biotech (NASDAQ: KRYS) will present multiple programs at scientific conferences in May and June 2026. Presentations cover gene therapy vectors for primary ciliary dyskinesia, interim CORAL-1 cystic fibrosis results, and an inhaled HSV-based immunotherapy plus pembrolizumab in NSCLC.
Slides and posters will be posted to the company’s Investor website after each conference.
Krystal Biotech (NASDAQ: KRYS) will report first quarter 2026 financial results on Monday, May 4, 2026, released prior to the open of U.S. markets.
Management will host a conference call and webcast at 8:30 AM ET on May 4, 2026 to discuss results and provide a business update. A replay will be available for at least 30 days on the company investor website.
Krystal Biotech (NASDAQ: KRYS) will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 in Boston. Company executives will participate in a fireside chat at 3:10 pm ET and hold investor meetings that day. A webcast will be available beginning at 3:10 pm ET and posted on the Investors section of the company website.